Commentary Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.46439/hematol.3.010
Taking BAFF-R targeting CAR T-cells on the road
Martha E. Gadd1, Hong Qin1,2,*
- 1Regenerative Immunotherapy and CAR-T Translational Research Program, Mayo Clinic, Jacksonville, FL, USA
- 2Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA
Corresponding Author
Hong Qin, Qin.Hong@mayo.edu
Received Date: January 29, 2024
Accepted Date: February 08, 2024
Gadd ME, Qin H. Taking BAFF-R targeting CAR T-cells on the road. J Clin Exp Hematol. 2024;3(1):1-3.
Copyright: © 2024 Gadd ME, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
EBV-positive Intravascular Large B-cell Lymphoma
Intravascular large B-cell lymphoma (IVLBCL) is a rare and specific variant of diffuse large B-cell lymphoma (DLBCL). Epstein-Barr virus (EBV)-positive IVLBCL is particularly rare and highly aggressive. Up to present, only a few cases of EBV-positive IVLBCL have been reported in the literature. Here, we would like to further explore its clinicopathological and molecular features to ensure the awareness and accurate diagnosis of this entity.
FHIT as a biomarker for early screening of adult T-cell leukemia
Adult T-cell leukemia (ATL) is an incurable leukemia deriving from human T-cell leukemia virus (HTLV-I) infected cells. In our most recent study, we discovered that methylation of the tumor suppressor, fragile histidine triad gene (FHIT), exists in the majority of acute and chronic ATL patients. Methylation was seen in non-tumorigenic cells, in cells with low levels of HTLV-I integrated DNA, in longitudinal samples from HTLV